Status:
COMPLETED
Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients
Lead Sponsor:
University Medical Center Groningen
Conditions:
Crohn Disease
Colitis, Ulcerative
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Summary Vision Study Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic idiopathic inflammatory bowel diseases (IBD). Vedolizumab is a humanized monoclonal antibody against α4β7 integrin, c...
Eligibility Criteria
Inclusion
- Established diagnosis of IBD, or Ulcerative Colitis (UC) or Crohn's Disease (CD).
- Vedolizumab naïve and eligible for vedolizumab treatment.
- Age: 18 years or older.
- Written informed consent.
Exclusion
- Prior vedolizumab treatment
- Vedolizumab contraindicated as therapy
- Pregnancy or breast feeding.
- Patients younger than 18 years old
Key Trial Info
Start Date :
November 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04112212
Start Date
November 4 2020
End Date
January 1 2023
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ